Report copyright - What science can do - AstraZeneca...H1 2019 H2 2019 H2 2019 Imfinzi + tremelimumab (NEPTUNE) PD-L1 mAb + CTLA-4 mAb 1st line NSCLC H2 2019 H2 2019 H2 2019 2020 Lumoxiti (PLAIT) anti-CD22
Please pass captcha verification before submit form